AbCellera partners with Vertex to develop multispecific T-cell engagers for autoimmune diseases, other conditions
Vertex Pharmaceuticals Inc. Stock Underperforms Wednesday When Compared To Competitors
Revolution Medicines to report Q2 financial results after market close, hosts webcast update
Vertex Pharmaceuticals Inc. Stock Underperforms Tuesday When Compared To Competitors Despite Daily Gains
ABN Amro Investment Solutions Purchases Shares of 6,794 Revolution Medicines, Inc. $RVMD
Cytokinetics CEO Robert I. Blum disposes of 7,500 common shares for $606,525